Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics
RXRX Price/Volume Stats
Current price | $9.97 | 52-week high | $16.75 |
Prev. close | $10.17 | 52-week low | $4.54 |
Day low | $9.94 | Volume | 5,441,600 |
Day high | $10.28 | Avg. volume | 7,178,618 |
50-day MA | $11.10 | Dividend yield | N/A |
200-day MA | $9.32 | Market Cap | 2.34B |
RXRX Stock Price Chart Interactive Chart >
RXRX POWR Grades
- RXRX scores best on the Momentum dimension, with a Momentum rank ahead of 27.6% of US stocks.
- RXRX's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- RXRX ranks lowest in Sentiment; there it ranks in the 0th percentile.
RXRX Stock Summary
- RXRX's went public 2.72 years ago, making it older than just 7.85% of listed US stocks we're tracking.
- With a price/sales ratio of 44.32, RECURSION PHARMACEUTICALS INC has a higher such ratio than 96.34% of stocks in our set.
- As for revenue growth, note that RXRX's revenue has grown 65.02% over the past 12 months; that beats the revenue growth of 92.97% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to RECURSION PHARMACEUTICALS INC, a group of peers worth examining would be ALGS, TSP, FUSN, SLDP, and CRIS.
- RXRX's SEC filings can be seen here. And to visit RECURSION PHARMACEUTICALS INC's official web site, go to www.recursion.com.
RXRX Valuation Summary
- In comparison to the median Healthcare stock, RXRX's price/sales ratio is 973.81% higher, now standing at 45.1.
- Over the past 33 months, RXRX's price/earnings ratio has gone up 50.2.
Below are key valuation metrics over time for RXRX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
RXRX | 2023-12-29 | 45.1 | 4.9 | -7.3 | -6.1 |
RXRX | 2023-12-28 | 48.5 | 5.2 | -7.9 | -6.7 |
RXRX | 2023-12-27 | 48.9 | 5.3 | -7.9 | -6.8 |
RXRX | 2023-12-26 | 49.4 | 5.3 | -8.0 | -6.8 |
RXRX | 2023-12-22 | 47.2 | 5.1 | -7.6 | -6.5 |
RXRX | 2023-12-21 | 45.0 | 4.9 | -7.3 | -6.1 |
RXRX Price Target
For more insight on analysts targets of RXRX, see our RXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $32.40 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Recursion Pharmaceuticals Inc. (RXRX) Company Bio
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Latest RXRX News From Around the Web
Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
40 Cities with the Highest Life Expectancy in the USIn this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US. Life expectancy of a newborn […] |
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery IndustryScreening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries w |
3 Genomics Stocks to Unlock the Future of MedicineGenomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. |
2 Cathie Wood Stocks That Might Be Smart Buys Right NowThese two biotech stocks hold enormous potential. |
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
RXRX Price Returns
1-mo | -22.95% |
3-mo | 1.12% |
6-mo | 30.33% |
1-year | 54.57% |
3-year | N/A |
5-year | N/A |
YTD | 1.12% |
2023 | 27.89% |
2022 | -54.99% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...